Abstract
This perspective outlines the challenges to joint development of a predictive genetic diagnostic with a drug to enhance the efficacy or safety of therapy with the targeted drug. Joint development requires a discovery approach to identify the genetic marker(s), followed by a replication or validation process confirming the clinical utility of the genetic marker(s) in predicting response to the targeted drug. The promise of overcoming these hurdles is that combined use of the genetic diagnostic linked to the drug provides additional scientific information to assist the clinician in their choice of therapeutic interventions on a patient-by-patient basis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
